BACKGROUND: Children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma achieve an event-free survival at 5 years of about 90% after treatment with vincristine, etoposide, prednisone, and doxorubicin (OEPA) followed by cyclophosphamide, vincristine, prednisone, and procarbazine (COPP) and radiotherapy, but long-term treatment effects affect survival and quality of life. We aimed to investigate whether radiotherapy can be omitted in patients with morphological and metabolic adequate response to OEPA and whether modified consolidation chemotherapy reduces gonadotoxicity. METHODS: Our study was designed as a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial, and was carried out at 186 hospital sites across 16 European countries. Children and adolescents with newly diagnosed intermediate-stage (treatment group 2) and advanced-stage (treatment group 3) classical Hodgkin lymphoma who were younger than 18 years and stratified according to risk using Ann Arbor disease stages IIAE, IIB, IIBE, IIIA, IIIAE, IIIB, IIIBE, and all stages IV (A, B, AE, and BE) were included in the study. Patients with early disease (treatment group 1) were excluded from this analysis. All patients were treated with two cycles of OEPA (1·5 mg/m2 vincristine taken intravenously capped at 2 mg, on days 1, 8, and 15; 125 mg/m2 etoposide taken intravenously on days 1-5; 60 mg/m2 prednisone taken orally on days 1-15; and 40 mg/m2 doxorubicin taken intravenously on days 1 and 15). Patients were randomly assigned to two (treatment group 2) or four (treatment group 3) cycles of COPP (500 mg/m2 cyclophosphamide taken intravenously on days 1 and 8; 1·5 mg/m2 vincristine taken intravenously capped at 2 mg, on days 1 and 8; 40 mg/m2 prednisone taken orally on days 1 to 15; and 100 mg/m2 procarbazine taken orally on days 1 to 15) or COPDAC, which was identical to COPP except that 250 mg/m2 dacarbazine administered intravenously on days 1 to 3 replaced procarbazine. The method of randomisation (1:1) was minimisation with stochastic component and was centrally stratified by treatment group, country, trial sites, and sex. The primary endpoint was event-free survival, defined as time from treatment start until the first of the following events: death from any cause, progression or relapse of classical Hodgkin lymphoma, or occurrence of secondary malignancy. The primary objectives were maintaining 90% event-free survival at 5 years in patients with adequate response to OEPA treated without radiotherapy and to exclude a decrease of 8% in event-free survival at 5 years in the embedded COPDAC versus COPP randomisation to show non-inferiority of COPDAC. Efficacy analyses are reported per protocol and safety in the intention-to-treat population. The trial is registered with ClinicalTrials.gov (trial number NCT00433459) and EUDRACT (trial number 2006-000995-33), and is closed to recruitment. FINDINGS: Between Jan 31, 2007, and Jan 30, 2013, 2102 patients were recruited. 737 (35%) of the 2102 recruited patients were in treatment group 1 (early-stage disease) and were not included in our analysis. 1365 (65%) of the 2102 patients were in treatment group 2 (intermediate-stage disease; n=455) and treatment group 3 (advanced-stage disease; n=910). Of these 1365, 1287 (94%) patients (435 [34%] of 1287 in treatment group 2 and 852 [66%] of 1287 in treatment group 3) were included in the titration trial per-protocol analysis. 937 (69%) of 1365 patients were randomly assigned to COPP (n=471) or COPDAC (n=466) in the embedded trial. Median follow-up was 66·5 months (IQR 62·7-71·7). Of 1287 patients in the per-protocol group, 514 (40%) had an adequate response to treatment and were not treated with radiotherapy (215 [49%] of 435 in treatment group 2 and 299 [35%] of 852 in treatment group 3). 773 (60%) of 1287 patients with inadequate response were scheduled for radiotherapy (220 [51%] of 435 in the treatment group 2 and 553 [65%] of 852 in treatment group 3. In patients who responded adequately, event-free survival rates at 5 years were 90·1% (95% CI 87·5-92·7). event-free survival rates at 5 years in 892 patients who were randomly assigned to treatment and analysed per protocol were 89·9% (95% CI 87·1-92·8) for COPP (n=444) versus 86·1% (82·9-89·4) for COPDAC (n=448). The COPDAC minus COPP difference in event-free survival at 5 years was -3·7% (-8·0 to 0·6). The most common grade 3-4 adverse events (intention-to-treat population) were decreased haemoglobin (205 [15%] of 1365 patients during OEPA vs 37 [7%] of 528 treated with COPP vs 20 [2%] of 819 treated with COPDAC), decreased white blood cells (815 [60%] vs 231 [44%] vs 84 [10%]), and decreased neutrophils (1160 [85%] vs 223 [42%] vs 174 [21%]). One patient in treatment group 2 died of sepsis after the first cycle of OEPA; no other treatment-related deaths occurred. INTERPRETATION: Our results show that radiotherapy can be omitted in patients who adequately respond to treatment, when consolidated with COPP or COPDAC. COPDAC might be less effective, but is substantially less gonadotoxic than COPP. A high proportion of patients could therefore be spared radiotherapy, eventually reducing the late effects of treatment. With more refined criteria for response assessment, the number of patients who receive radiotherapy will be further decreased. FUNDING: Deutsche Krebshilfe, Elternverein für Krebs-und leukämiekranke Kinder Gießen, Kinderkrebsstiftung Mainz, Tour der Hoffnung, Menschen für Kinder, Programme Hospitalier de Recherche Clinique, and Cancer Research UK.

Children and Young People's Cancer Service University College Hospital London London UK

Clinical Department of Paediatric Haematology Oncology and Stem Cell Transplantation University Medical Centre Ljubljana and University Children's Hospital Ljubljana Slovenia

Department of Cellular Pathology University College Hospital London London UK

Department of Nuclear Medicine Tenon Hospital APHP and Sorbonne Université Paris France

Department of Nuclear Medicine University of Leipzig Leipzig Germany

Department of Paediatric Haematology and Oncology Medical University of Vienna Vienna Austria

Department of Paediatric Haematology and Oncology National Institute of Children's Disease and Comenius University Bratislava Slovakia

Department of Paediatric Haematology and Oncology Royal Hospital for Children and Young People and University of Edinburgh Edinburgh UK

Department of Paediatric Haematology and Oncology University Hospital Motol Prague Czech Republic

Department of Paediatric Haematology Oncology Sorbonne Université and APHP SIRIC CURAMUS Hôpital a Trousseau Paris France

Department of Paediatric Oncology and Haematology Institute of Paediatrics Jagiellonian University Medical College Krakow Poland

Department of Paediatric Oncology at Astrid Lindgrens Children's Hospital Karolinska University Hospital Stockholm Sweden

Department of Paediatric Oncology Justus Liebig University Giessen Giessen Germany

Department of Paediatric Oncology Justus Liebig University Giessen Giessen Germany; Medical Faculty Martin Luther University Halle Wittenberg Halle Germany

Department of Paediatrics and Adolescent Medicine The Juliane Marie Centre University Hospital Rigshospitalet Copenhagen Denmark

Department of Paediatrics University of Schleswig Holstein Kiel Germany

Department of Pathology Armand Trousseau Hospital Paris France

Department of Radiation Oncology Martin Luther University Halle Wittenberg Halle Germany

Department of Radiology University Hospital Halle Halle Germany

Hospital Universitario Virgen Macarena Universidad de Sevilla Sevilla Spain

Institute for Medical Informatics Statistics and Epidemiology University of Leipzig Leipzig Germany

Institute of Pathology Justus Liebig University Giessen Giessen Germany

MRC Centre for Reproductive Health Queens Medical Research Institute University of Edinburgh Edinburgh UK

Oslo Universitetssykehus Radiumhospitalet Oslo Norway

Our Lady's Hospital for Children's Health Dublin Ireland

Paediatric Haematology and Oncology Department of Oncology University Hospitals Leuven KU Leuven Leuven Belgium

Paediatric Haematology and Oncology Department of Paediatrics Inselspital Bern University Hospital University of Bern Bern Switzerland

Princess Máxima Centre for Paediatric Oncology Utrecht and Erasmus Sophia Children's Hospital Rotterdam The Netherlands

Service d'Hématologie Pédiatrique Hôpital Robert Debré Paris France

St Anna Children's Hospital Medical University of Vienna Vienna Austria

Strahlentherapie AKH Wien Medizinische Universitätsklinik Wien Vienna Austria

Komentář v

Lancet Oncol. 2022 Jan;23(1):11-13. doi: 10.1016/S1470-2045(21)00544-1. PubMed

Erratum v

Lancet Oncol. 2022 Feb;23(2):e59. doi: 10.1016/S1470-2045(22)00029-8. PubMed

Komentář v

Strahlenther Onkol. 2022 Jun;198(6):593-594. doi: 10.1007/s00066-022-01923-4. PubMed

Zobrazit více v PubMed

Schellong G, Bramswig J, Ludwig R, et al. Combined treatment strategy in over 200 children with Hodgkin's disease: graduated chemotherapy, involved field irradiation with low dosage and selective splenectomy. A report of the cooperative therapy study DAL-HD-82. Klin Padiatr. 1986;198:137–146. PubMed

Schellong G, Potter R, Bramswig J, et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol. 1999;17:3736–3744. PubMed

Weiner MA, Leventhal B, Brecher ML, et al. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol. 1997;15:2769–2779. PubMed

Donaldson SS, Hudson MM, Lamborn KR, et al. VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial. J Clin Oncol. 2002;20:3081–3087. PubMed

Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009;114:2051–2059. PubMed PMC

Friedman DL, Chen L, Wolden S, et al. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. J Clin Oncol. 2014;32:3651–3658. PubMed PMC

Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med. 1996;334:745–751. PubMed

Schellong G, Riepenhausen M, Ehlert K, et al. Breast cancer in young women after treatment for Hodgkin's disease during childhood or adolescence: an observational study with up to 33-year follow-up. Dtsch Arztebl Int. 2014;111:3–9. PubMed PMC

van Nimwegen FA, Ntentas G, Darby SC, et al. Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood. 2017;129:2257–2265. PubMed PMC

Hasenclever D. The disappearance of prognostic factors in Hodgkin's disease. Ann Oncol. 2002;13(suppl 1):75–78. PubMed

Mauz-Korholz C, Hasenclever D, Dorffel W, et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010;28:3680–3686. PubMed

Brämswig JH, Heimes U, Heiermann E, Schlegel W, Nieschlag E, Schellong G. The effects of different cumulative doses of chemotherapy on testicular function. Results in 75 patients treated for Hodgkin's disease during childhood or adolescence. Cancer. 1990;65:1298–1302. PubMed

Hassel JU, Brämswig JH, Schlegel W, Schellong G. Testicular function after OPA/COMP chemotherapy without procarbazine in boys with Hodgkin's disease. Results in 25 patients of the DAL-HD-85 study. Klin Padiatr. 1991;203:268–272. PubMed

Sieniawski M, Reineke T, Josting A, et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Ann Oncol. 2008;19:1795–1801. PubMed

Behringer K, Mueller H, Goergen H, et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol. 2013;31:231–239. PubMed

Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000;47:13–47. PubMed

Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–3068. PubMed PMC

WHO . Fifth edition. World Health Organization; Geneva: 2010. WHO laboratory manual for the examination and processing of human semen.

Kelsey TW, McConville L, Edgar AB, et al. Follicle stimulating hormone is an accurate predictor of azoospermia in childhood cancer survivors. PLoS One. 2017;12 PubMed PMC

Kelsey TW, Miles A, Mitchell RT, et al. A normative model of serum inhibin B in young males. PLoS One. 2016;11 PubMed PMC

Webber L, Davies M, Anderson R, et al. ESHRE guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31:926–937. PubMed

Schellong GM. The German cooperative therapy studies. An approach to minimize treatment modalities and invasive staging procedures. Cancer Treat Res. 1989;41:277–289. PubMed

Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379:1791–1799. PubMed

Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med. 2015;372:1598–1607. PubMed

Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. 2018;390:2790–2802. PubMed

Barrington SF, Kluge R. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur J Nucl Med Mol Imaging. 2017;44(suppl 1):97–110. PubMed PMC

Mauz-Körholz C, Hasenclever D, Holzendorf V, et al. Feasibility of VECOPA: a dose-intensive chemotherapy regimen for children and adolescents with intermediate and advanced stage Hodgkin's lymphoma: results of the GPOH-HD-2002/VECOPA pilot trial. Leuk Lymphoma. 2014;10:1–17. PubMed

Kelly KM, Cole PD, Pei Q, et al. Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group. Br J Haematol. 2019;187:39–48. PubMed PMC

Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med. 2011;365:203–212. PubMed

Clinicaltrials.gov

EuroNet-PHL-C2 second international inter-group study for classical Hodgkin lymphoma in children and adolescents. 2016. http://clinicaltrials.gov/ct/show/NCT02684708

Transplant and Nontransplant Salvage Therapy in Pediatric Relapsed or Refractory Hodgkin Lymphoma: The EuroNet-PHL-R1 Phase 3 Nonrandomized Clinical Trial

Semen analysis and reproductive hormones in boys with classical Hodgkin lymphoma treated according to the EuroNet-PHL-C2 protocol

The impact of treatment for childhood classical Hodgkin lymphoma according to the EuroNet-PHL-C2 protocol on serum anti-Müllerian Hormone

Hodgkin lymphoma: hypodense lesions in mediastinal masses

Fertility-Preserving Treatments and Patient- and Parental Satisfaction on Fertility Counseling in a Cohort of Newly Diagnosed Boys and Girls with Childhood Hodgkin Lymphoma

Pulmonary lesions in early response assessment in pediatric Hodgkin lymphoma: prevalence and possible implications for initial staging

Prevention of activated brown adipose tissue on 18F-FDG-PET scans of young lymphoma patients: results of an ancillary study within the EuroNet-PHL-C2 trial

Optimized Whole-Body PET MRI Sequence Workflow in Pediatric Hodgkin Lymphoma Patients

The EHA Research Roadmap: Malignant Lymphoid Diseases

Zobrazit více v PubMed

ClinicalTrials.gov
NCT00433459